Bill

Bill > S00105


NY S00105

NY S00105
Requires health insurance policies to cover comprehensive genetic screening and FDA approved biomarker testing for ovarian and prostate cancers.


summary

Introduced
01/06/2021
In Committee
01/05/2022
Crossed Over
Passed
Dead
12/31/2022

Introduced Session

2021-2022 General Assembly

Bill Summary

AN ACT to amend the insurance law, in relation to requiring health insurance policies to fully cover comprehensive genetic testing and FDA approved biomarker testing for ovarian and prostate cancers

AI Summary

This bill requires health insurance policies to fully cover comprehensive genetic testing and FDA-approved biomarker testing for ovarian and prostate cancers. The coverage is mandatory, regardless of the patient's initial diagnosis, and is also extended to family members of cancer patients. The genetic results cannot be used against family members for insurance coverage purposes. All costs associated with this additional coverage must be borne solely by the insurer and are not subject to annual deductibles or coinsurance.

Committee Categories

Business and Industry

Sponsors (6)

Last Action

REFERRED TO INSURANCE (on 01/05/2022)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...